undamentalytics Newsletter

Van Plew Daniel P: insider trades

Officer at Regeneron Pharmaceuticals. No open-market purchases and 21 sales not made under a pre-set plan, reported from April 30, 2012 to February 16, 2024.

What happened after Van Plew Daniel P’s sales?

After their sales, the shares moved +3.9% against the index over 12 months on average (a negative figure means selling was the right call); 52% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Van Plew Daniel P: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 21 +0.4% −2.2% 52% 10 −0.84 0.42 No reliable evidence
Sales, 12 months after the report 21 +3.9% −1.2% 52% 10 0.30 0.77 No reliable evidence
Sales, 12 months after the trade 21 +3.0% −1.9% 57% 10 0.19 0.85 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Regeneron Pharmaceuticals REGN EVP & General Mgr, Industrial021April 30, 2012February 16, 2024

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
February 16, 2024February 14, 2024 REGN Sale $9,831,727 −2.8%−48.3%−52.5%
August 25, 2023August 24, 2023 REGN Sale $5,216,073 −7.0%+16.5%+14.1%
November 25, 2022November 23, 2022 REGN Sale $8,868,260 +3.7%−7.6%−6.2%
November 8, 2022November 7, 2022 REGN Sale $5,878,263 −7.6%−12.1%−7.3%
February 24, 2022February 23, 2022 REGN Sale $4,163,489 +17.6%+30.9%+28.8%
November 17, 2021November 16, 2021 REGN Sale $4,452,194 +2.1%+28.0%+28.9%
August 10, 2021August 10, 2021 REGN Sale $4,040,105 −4.4%+6.6%+8.1%
August 27, 2020August 25, 2020 REGN Sale $16,560,738 −18.8%−18.6%−22.8%
May 8, 2020May 7, 2020 REGN Sale $22,337,306 −9.3%−56.6%−60.4%
February 27, 2020February 26, 2020 REGN Sale $7,152,016 +34.5%−29.8%−26.1%
May 19, 2016May 18, 2016 REGN Sale $1,702,403 −2.2%+0.5%−0.8%
November 10, 2015November 10, 2015 REGN Sale $2,842,520 −23.5%−32.0%−31.9%
August 7, 2015August 6, 2015 REGN Sale $2,353,807 −3.5%−33.7%−34.4%
May 26, 2015May 26, 2015 REGN Sale $9,339,737 +8.4%−23.9%−22.3%
February 24, 2015February 23, 2015 REGN Sale $4,034,754 +20.9%−1.2%−1.9%
November 14, 2014November 13, 2014 REGN Sale $3,424,336 +3.4%+40.3%+35.1%
August 7, 2014August 7, 2014 REGN Sale $2,302,946 +5.8%+60.6%+59.9%
May 23, 2014May 23, 2014 REGN Sale $1,588,872 +7.9%+54.1%+57.3%
May 8, 2013May 7, 2013 REGN Sale $3,590,637 −8.4%−11.1%−8.5%
November 16, 2012November 16, 2012 REGN Sale $2,917,899 −9.6%+39.2%+39.5%
April 30, 2012April 30, 2012 REGN Sale $1,969,554 +1.8%+80.9%+67.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Van Plew Daniel P traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.